LABORATORY AND CLINICAL STUDIES OF CEFODIZIME IN PEDIATRIC FIELD

We have carried our laboratory and clinical studies on cefodizime (CDZM, THR-221). The results were summarized as follows. CDZM was given by 30-minute drip infusion to 2 children at a single dose of 10 mg/kg and to 2 children at a single dose of 20 mg/kg and to 3 children at a single dose of 40 mg/kg. After the 30-minute drip infusion, mean serum levels of CDZM obtained for the 3 dose levels were 76.16 ± 5.52 μg/ml, 170.49 ± 16.70 μg/ml, 270.01 ±50.44 μg/ml at the end of injection, respectivery, and serum half-lives were 2.03 ± 0.78 hours, 2.03 ± 0.38 hours, 2.28 ±0.30 hours, respectively. The mean urinary excretion rate of CDZM were 83.3 ±22.3%, 73.1 ±13.9%, 51.1±8.5% in the first 8 hours after the 30-minute drip infusion of 10 mg/kg, 20 mg/kg, 40 mg/kg, respectively. Treatment with CDZM was made in 28 cases of pediatric bacterial infections; 5 cases of tonsillitis, 2 cases of bronchitis, 10 cases of pneumonia, 6 cases of enteritis, 3 cases of urinary tract infection and 1 case each of maxillary sinusitis and laryngitis. Results obtained were excellent in 13 cases, good in 7 cases, fair in 2 cases, poor in 6 cases. No significant side effect due to the drug was observed except one case of thrombocytosis and 2 cases each of elevated GOT and elevated GOT and GPT.